Organization (Academic)
VinUniversity
ClinicalTrials.gov lists VinUniversity as lead sponsor of 31 trials, counting the companies grouped under it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
17 sections measured, none recorded
This page covers VinUniversity and 1 company grouped under it: 31 lead-sponsored trials (3 its own, 28 in the grouped companies) and 2 legal-entity registrations (1 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Vinmec Research Institute of Stem Cell and Gene Technology | 28 | 1 |
Disease areas (33)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Fibrosis | 4 |
| Liver Cirrhosis | 4 |
| Autism Spectrum Disorder | 3 |
| Biliary Atresia | 3 |
| COVID-19 | 2 |
Showing 5 of 33 disease areas.
Trials by start year as sponsor or collaborator (3)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 1 |
No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 3 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
Journals published in (69)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of pediatric surgery | 8 |
| The Journal of urology | 6 |
| Journal of pediatric urology | 5 |
| Pediatric surgery international | 5 |
| Journal of laparoendoscopic & advanced surgical techniques. Part A | 4 |
Showing 5 of 69 journals.
Organization relationships (4)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Gwoxi Stem cell applied technology Company | Co sponsors trial with | 1 |
| Vinmec Health Care System (Vingroup Joint Stock Company) | Co sponsors trial with | 1 |
| Number 2 Children's Hospital, Ho Chi Minh City | Co sponsors trial with | 1 |
| National Institute of Hematology and Blood Transfusion, Vietnam | Co sponsors trial with | 1 |
Latest dated events (34)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-02-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 34 events.
Biomarkers this organization publishes on (78)
Shown in this order: most publications first.
Showing 5 of 78 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, approved assets, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarker capability evidence.